ETH-BTC Takes a Dip: Ethereum Loses Key Support, Hitting Lowest Level Since December 2020 – A Playful Peek into Crypto’s Rollercoaster Ride

Ouch! Ethereum Takes a Hit: A 11.8% Dip in 24 Hours It’s a rollercoaster ride in the cryptocurrency world once again! Ethereum (ETH), the second-largest cryptocurrency by market capitalization, has taken a tumble, shedding a hefty 11.8% of its value in just the past 24 hours. Yikes! The Sorrowful Tale of Ethereum’s Recent Slump Market…

Read More

Bitcoin Dips Below $80,000: ETF Investors Exit as BTC Price Slips Beneath Crucial Support Level

Bitcoin’s Dramatic Price Drop: A Trifecta of Factors Bitcoin, the world’s largest and most well-known cryptocurrency, has experienced a significant price drop in recent weeks. As of now, it hovers around the $72,000 mark, representing a 27% decline from its all-time high of nearly $100,000. ETF Outflows One of the primary reasons behind this downturn…

Read More

Metaplanet’s $13.5 Million Bitcoin Purchase: Acquiring 162 BTC with Newly Issued Bonds

Metaplanet’s Bitcoin Acquisition: Metaplanet, a formerly known budget hotel operator, made headlines recently with its strategic move into the Bitcoin market. The company announced that it had purchased 162 Bitcoins for an investment of $13.5 million. Funding the Bitcoin Purchase To finance this acquisition, Metaplanet issued zero-coupon bonds. These bonds do not pay interest to…

Read More

“Marriott International: One of Fortune’s Most Admired Companies in the World!”

Marriott International Named Among World’s Most Admired Companies February 3, 2025 Marriott International has once again solidified its position as one of the top companies in the world, as it was recently announced that it has been named among FORTUNE Magazine’s World’s Most Admired Companies. This prestigious recognition is a testament to Marriott’s commitment to…

Read More

Nuvectis Pharma’s NXP900 Shines in NSCLC Treatment: Superior Efficacy with Tagrisso, According to Cleveland Clinic Study Post New Buy Recommendation

New Study Shows Superior Efficacy of Nuvectis Pharma’s NXP900 in Combination with Osimertinib for Non-Small Cell Lung Cancer In a groundbreaking development, Nuvectis Pharma (NASDAQ: NVCT) has announced that new research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has shown the superior efficacy of NXP900 when used in conjunction…

Read More